<DOC>
	<DOC>NCT02830477</DOC>
	<brief_summary>The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose &amp; dosing frequency, reason for choice of treatment regimen, FVIII product switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data (if performed), KOVALTRY consumption, as well as safety data.</brief_summary>
	<brief_title>Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</brief_title>
	<detailed_description>Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY as prophylaxis therapy.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patients diagnosed with moderate to severe hemophilia A (≤ 5% Factor VIII levels) Any age ≥ 50 exposure days (EDs) to any FVIII product Patients with no history of inhibitors Currently on (started within 3 months of study enrollment) or plan to start prophylaxis therapy with KOVALTRY Written informed consent Patients participating in an investigational program with interventions outside of routine clinical practice Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Previously treated patients</keyword>
</DOC>